Abstract
Transfusions that are ABO compatible but not group identical (mismatched) are given for a variety of reasons including inventory availability, avoiding wastage from outdating, and clinical urgency. A recent observation at our centre suggested that patient outcome was different for those patients that received a transfusion of units with a compatible but mismatched ABO group compared to those receiving ABO group identical blood. Hence, we performed a retrospective hospital registry study to explore the association between mismatched blood and in-hospital mortality in transfused patients.
Our patient/blood utilization database included 35,487 transfused hospitalized patients from 3 acute care academic centres from April 1, 2002 to October 31, 2011. Information on transfused RBCs included duration of storage (days) and ABO type. Patient data included: sex; age; hemoglobin; creatinine; diagnosis; interventions; ABO blood group and hospital discharge status. Factors associated with mismatched blood and in-hospital mortality were examined using generalized estimating equations to account for the potential serial dependence over multiple transfusions. The effect of exposure to ABO mismatched blood on in-hospital death was examined through Cox regression with time-dependent strata defined by: year of first admission; disease group; and the cumulative number of units transfused (≤ 7 days of storage; > 7 days but ≤ 28 days storage; and, >28 days of storage); and, controlling for available baseline and time-varying characteristics.
18,843 patients (blood groups A, B and AB), with complete covariates contributed to the analysis. Factors associated with transfusion of mismatched blood included: younger patient age (p<0.0001); lower hemoglobin (p<0.0001); higher creatinine (p<0.0001); intervention during hospitalization (OR=4.6, p<0.0001); and, patient ABO group whereby blood types A and B were much less likely to receive a mismatched unit compared to type AB patients (p<0.0001). There was a statistically significant interaction between patient blood type and the effect of receiving mismatched blood (p=0.034) with type A patients incurring a 79% higher risk of death (RR=1.79, 95% CI: 1.20, 2.67; p=0.0047); other patient blood types did not suggest increased risk. Similar results were observed when suspected trauma patients (≥ 6 units within 24 hours) were excluded from the analysis (Table 1).
. | Full Cohort N=18,843 . | Full Cohort excluding Trauma Patients (≥ 6 units in 24 hours) N=17,435 . | ||||
---|---|---|---|---|---|---|
. | RR . | 95% CI . | p . | RR . | 95% CI . | p . |
ABO Mismatch vs no mismatch | 1.22 | 0.92, 1.63 | 0.1732 | 1.14 | 0.84, 1.55 | 0.3999 |
Mismatch by Patients ABO group | ||||||
A: mismatch vs no mismatch | 1.79 | 1.20, 2.67 | 0.0047 | 1.68 | 1.08, 2.62 | 0.0216 |
B: mismatch vs no mismatch | 0.64 | 0.30, 1.34 | 0.2319 | 0.72 | 0.34, 1.50 | 0.3793 |
AB: mismatch vs no mismatch | 1.01 | 0.62, 1.65 | 0.9674 | 0.91 | 0.55, 1.51 | 0.7189 |
Interaction test (2df) | 0.0340 | 0.0806 |
. | Full Cohort N=18,843 . | Full Cohort excluding Trauma Patients (≥ 6 units in 24 hours) N=17,435 . | ||||
---|---|---|---|---|---|---|
. | RR . | 95% CI . | p . | RR . | 95% CI . | p . |
ABO Mismatch vs no mismatch | 1.22 | 0.92, 1.63 | 0.1732 | 1.14 | 0.84, 1.55 | 0.3999 |
Mismatch by Patients ABO group | ||||||
A: mismatch vs no mismatch | 1.79 | 1.20, 2.67 | 0.0047 | 1.68 | 1.08, 2.62 | 0.0216 |
B: mismatch vs no mismatch | 0.64 | 0.30, 1.34 | 0.2319 | 0.72 | 0.34, 1.50 | 0.3793 |
AB: mismatch vs no mismatch | 1.01 | 0.62, 1.65 | 0.9674 | 0.91 | 0.55, 1.51 | 0.7189 |
Interaction test (2df) | 0.0340 | 0.0806 |
Controlling for known potential confounders through Cox regression yielded evidence of increased risk of in-hospital mortality among blood type A patients receiving group O red cells. This association remained after suspected trauma patients were excluded from the analyses. Further study of the association observed in this study is warranted.
Cook:CIHR: Research Funding. Heddle:CIHR: Research Funding; Canadian Blood Services: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Health Canada: Research Funding. Eikelboom:CIHR: Research Funding.
Author notes
Asterisk with author names denotes non-ASH members.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal